CPHI (China Pharma Holding) Other Stockholders Equity: $-0.18 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPHI China Pharma Holding Inc CPHI
26 GF Score
Price $1.10
GF Value $0.24
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is China Pharma Holding Other Stockholders Equity?

China Pharma Holding CPHI -10.57% 26 Other Stockholders Equity is $-0.18 Mil as of Mar. 2026. GuruFocus rates CPHI with a GF Score™ of 26/100 and a GF Value™ of $0.24 (Significantly Overvalued). The stock has 5 warning signs investors should review.

China Pharma Holding's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.18 Mil.

China Pharma Holding's quarterly Other Stockholders Equity declined from Sep. 2025 ($-0.18 Mil) to Dec. 2025 ($-0.18 Mil) but then increased from Dec. 2025 ($-0.18 Mil) to Mar. 2026 ($-0.18 Mil).

China Pharma Holding's annual Other Stockholders Equity declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.18 Mil) and declined from Dec. 2024 ($-0.18 Mil) to Dec. 2025 ($-0.18 Mil).

China Pharma Holding Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for China Pharma Holding's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Pharma Holding Other Stockholders Equity Chart

China Pharma Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.18 -0.18

China Pharma Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.18 -0.18 -0.18 -0.18
CPHI
26GF Score
China Pharma Holding Inc CPHI
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Pharma Holding Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.18 Mil mean?
China Pharma Holding (CPHI) has a Other Stockholders Equity of $-0.18 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on China Pharma Holding and its competitors.
Is China Pharma Holding's Other Stockholders Equity too high?
China Pharma Holding's current Other Stockholders Equity is $-0.18 Mil. Overall, China Pharma Holding has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Other Stockholders Equity compare to TXMD and RMTI?
China Pharma Holding's Other Stockholders Equity of $-0.18 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on China Pharma Holding and its competitors. China Pharma Holding's current Other Stockholders Equity is $-0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
Based on GuruFocus' analysis, China Pharma Holding (CPHI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $1.10 — trading 358.3% above its estimated fair value. The current Other Stockholders Equity is $-0.18 Mil. China Pharma Holding's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For China Pharma Holding (CPHI), the current Other Stockholders Equity is $-0.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Pharma Holding (CPHI) Overvalued in 2026?

Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued. The current stock price of $1.10 is trading 358.3% above its estimated GF Value™ of $0.24. GuruFocus considers China Pharma Holding to be Significantly Overvalued.

Key valuation signals for CPHI:

  • Other Stockholders Equity: $-0.18 Mil
  • GF Value™: $0.24 vs. price of $1.10 (358.3% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Pharma Holding Business Description

Address No. 17, Jinpan Road, Second Floor, Jiahai Building, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score

Get the complete analysis for CPHI

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.10
Price
$0.24
GF Value